However, by GEP and survival analyses dissecting c-Rel function and prognostic impact with and without concurrent activation of other NF-κB subunits, our results suggested that the oncogenic c-Rel dimers with clinical significance are likely predominated of c-Rel/p65 and c-Rel/p50 in ABC-DLBCL, and potentially c-Rel/c-Rel dimers in GCB-DLBCL, which are all activated via the canonical pathway [4, 17, 68, 69]. The gene discussed is REL; the disease is diffuse large B-cell lymphoma.